GlobeVerge
Home / business
MARKETS
AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has
Caution ahead70%
PositivePossible support for stability, investment or market confidence
RiskInflation, volatility, borrowing costs or weaker growth
More in Finance
GlobeVerge Signal: A transparent, keyword-based read on this story's tone and stakes—not financial, political or safety advice. The summary above is the original publisher's excerpt, not AI-generated or rewritten by GlobeVerge. Open the original source link before acting on any story.